Cargando…
Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma: Erratum
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797557/ https://www.ncbi.nlm.nih.gov/pubmed/35089237 http://dx.doi.org/10.1097/MD.0000000000028714 |
Ejemplares similares
-
Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019) -
Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022) -
Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
por: Puri, Vandana, et al.
Publicado: (2011) -
Quantum Dot-Based Immunofluorescent Imaging of Ki67 and Identification of Prognostic Value in HER2-Positive (Non-Luminal) Breast Cancer [Erratum]
Publicado: (2023) -
Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)